Making Existing Treatments Better
At OncoSec, we are pioneering technologies that concentrate the power of anti-cancer therapies while minimizing or eliminating the damage they can cause to healthy tissues.
The breakthrough hinges on a proprietary process called electroporation, which uses an electrical pulse to create temporary pores in cancer cells. Clinically proven chemotherapeutics or gene-based cytokines are then delivered through these pores, at doses lower than what would normally be delivered systemically. The result is a more potentially effective treatment with fewer side effects.
Supported by extensive research and development and a comprehensive patent portfolio, OncoSec is now a world leader in this emerging technology. Our technology development includes the design and manufacture of medical-grade electrical pulse generators, treatment applicators, and software that are adaptable for different clinical applications. The technology and methods of use are all patented intellectual property.
These proprietary elements, along with our clinical trial experience and expertise in using these technologies, have helped us to consolidate our position as the leading proponents of this promising treatment for solid tumors.
OncoSec Medical System (OMS):
Using a process called electroporation, brief electric pulses create temporary pores in the cell membrane.
An anti-cancer agent previously injected into the area can flow through the pores into the targeted cells.
By increasing the porosity of cancerous cells, our technology looks to increase the local delivery of certain applied therapies by a factor of up to 4000.
Conventional cancer treatments can’t distinguish between cancerous and normal cells, which means that excessive dosages must be administered in order to reach cancerous cells.
How it works
The OMS electroporation platform consists of a generator and applicator:
1The generator creates a pulsed electric field that temporarily increases the porosity of cell membranes within the treatment field.
2The hand-held applicator supplies a series of short-duration electrical pulses of specific voltage through a series of needles.
3Together, the action of the generator and applicator creates a rotating array of pulses that uniformly subject the targeted cell membranes to electroporation.
Currently, the OMS has been tested for use with two anti-cancer therapies:
ImmunoPulse delivers instructions to the cell (DNA IL-12) to produce a protein that activates an immune response against cancer cells.
NeoPulse delivers bleomycin, an approved anti-cancer drug that specifically targets and destroys cancer cells.